SCMP Sucampo Pharmaceuticals Inc.

10.43
+0.07  (1%)
Previous Close 10.35
Open 10.35
Price To book 12.27
Market Cap 486189933
Shares 46,636,924
Volume 61,418
Short Ratio 9.10
Av. Daily Volume 488,438

SEC filingsSee all SEC filings

  1. 8-K - Current report 171206614
  2. 8-K/A [Amend] - Current report 171172418
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 171167275
  4. 8-K - Current report 171167270
  5. 8-K/A [Amend] - Current report 171149073

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved April 23, 2013.
Amitiza/Lubiprostone
Opioid-induced bowel dysfunction
Cobiprostone development discontinued July 2016
Cobiprostone
Oral Mucositis
PDUFA date for sNDA under priority review January 28, 2018.
Lubiprostone
Pediatric functional constipation
Phase 2a trial did not meet endpoints
Cobiprostone
proton pump inhibitor (PPI)-refractory non-erosive reflux disease (NERD) or symptomatic gastroesophageal reflux disease (sGERD)

SEC Filings

  1. 8-K - Current report 171206614
  2. 8-K/A [Amend] - Current report 171172418
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 171167275
  4. 8-K - Current report 171167270
  5. 8-K/A [Amend] - Current report 171149073
  6. SC 13D/A [Amend] - General statement of acquisition of beneficial ownership 171107920
  7. SC 13D/A [Amend] - General statement of acquisition of beneficial ownership 171107909
  8. SC 13D/A [Amend] - General statement of acquisition of beneficial ownership 171107869
  9. 8-K - Current report 171101173
  10. 8-K - Current report 171094168